Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

Meet the Experts
Date and time:
29.09.2021 at 18:30 - 19:00 CEST
Corporate Event
Simon Heller; Athena Philis-Tsimikas;
European Association for the Study of Diabetes (EASD)
Industry session on the occasion of the 57th Annual Meeting of the European Association for the Study of Diabetes. Diabetes continues to be one of the fastest growing health challenges of our time. Despite the diversity of treatment options available to clinicians and patients, the chronic and progressive nature of diabetes often requires treatment intensification with a basal insulin. Many people with type 2 diabetes struggle to achieve effective blood sugar control due to barriers like regimen complexity, injection burden, and reluctance to initiate insulin therapy. Novel approaches to diabetes treatment with insulins are therefore required to help more patients meet their treatment goals while minimising hypoglycaemia and reducing treatment complexity. This Novo Nordisk symposium will feature two renowned international experts in diabetes treatment: Drs Athena Philis-Tsimikas and Simon Heller. They will retrospectively look back to the development of insulin over the last 100 years and share their insights into the utility of once-weekly basal insulins. A particular focus will be on insulin icodec, the first-in-class once-weekly insulin currently in phase 3 development, as well as patient and physician perspectives on how once-weekly insulin options may help get patients to target. Altogether, this symposium will show how the new insulin treatment landscape is moving beyond just glycaemic control to ultimately improve patient care and diabetes-related outcomes.


A retrospective look: 100 years since insulin was discovered

Once-weekly basal insulins: From innovation to RCTs

Patient-centric care: How once-weekly options may help get patients to target

Questions from the audience


Athena Philis-Tsimikas - Speaker

Athena Philis-Tsimikas

Scripps Whittier Diabetes Institute at Scripps Health, UCSD’s Division of Endocrinology and Metabolism, San Diego, CA, USA

Athena Philis-Tsimikas is Corporate Vice President of the Scripps Whittier Diabetes Institute at Scripps Health in San Diego, California, USA, and Associate Clinical Professor of Medicine at UCSD’s Division of Endocrinology and Metabolism. She leads the Scripps Diabetes Care Line, which creates programmes and delivers diabetes services across five Scripps hospitals, 25 outpatient facilities, and the community. Dr Philis-Tsimikas has devoted more than 20 years’ research and clinical efforts to improving diabetes assessment, education, and management. 


Among other accomplishments, she developed and implemented the innovative Project Dulce programme, a collaboration between Scripps Health and San Diego area community clinics that emphasizes coordinated care management and relies on peer educators to deliver diabetes self-management education. She has also served as the Principal Investigator of numerous clinical trials.

Read full bio
Simon Heller - Speaker

Simon Heller

University of Sheffield, Sheffield Teaching Hospitals Foundation Trust, Sheffield, United Kingdom

Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, and Director of Research & Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK. Professor Heller’s research interests include physiological responses to hypoglycaemia and hypoglycaemia unawareness; the potential contribution of the pathophysiology of hypoglycaemia to sudden death in diabetes; and the use of insulin analogues and other technologies to reduce hypoglycaemia. He also runs research programmes on interventions to encourage more effective diabetes self-management.


He is national specialty lead for diabetes within the UK NIHR clinical research network and an NIHR senior investigator.  Professor Heller has authored more than 200 research articles and reviews and is a past editor of Diabetic Medicine.

Read full bio